Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 196

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides

Open access
Aartsma-Rus, Annemieke·2017·Nucleic Acid Therapeutics

Abstract

With the Food and Drug Administration (FDA) approval of nusinersen (tradename Spinraza) for treatment of spinal muscular atrophy patients on December 23 [1], 2016 brought us not one, but two approved splice modulating oligonucleotides to treat neuromuscular disorders.Eteplirsen, an oligonucleotide to treat a subset of Duchenne muscular dystrophy (DMD) patients, was approved earlier this year.However, where the approval of eteplirsen was highly controversial [2], this one seemed to be crystal clear: the drug was approved only 91 days after Bioeen filed the new drug application (NDA) with FDA, and the application was not referred to an FDA advisory committee because "outside expertise was not necessary and there were no controversial issues that would have benefited from advisory committee discussion" [3].Spinal muscular atrophy is an autosomal recessively inherited disease, that is characterized by progressive loss of motorneurons, leading to muscle atrophy and paralysation.Most patients (60%) suffer from the most severe form of the disease, type I SMA.Symptoms start in infants before 6 months of age, patients never achieve independent sitting, need intensive supportive care, including ventilation, and seldom live beyond two years of age.Type II and type III SMA are milder forms of the disease.For type II onset is after 6-18 months, patients are able to sit independently but never able to walk and can live 20-40 years with good supportive care.Type III SMA patients are able to walk, but generally loose this ability when disease progresses.Survival is normal.It should be noted that all types of SMA are severe and debilitating and that the term "milder" is only relative to the very severe type I SMA.There is a type IV SMA, with onset in adulthood (after 30 years of age) and a slowly progressive course, but this is a very rare form [4].

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/nat.2017.0665

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 196

Metadata

Authors
Aartsma-Rus, A.
Venue
Nucleic Acid Therapeutics
Published
2017-04
Volume
27
Issue
2
Pages
67-69
ISSN
  • 2159-3337 (ISSN-L)
  • 2159-3345
OpenAlex
W2595650684
Cited by
196
References
1
FWCI
11.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides. https://app.cochat.ai/papers/10.1089/nat.2017.0665
The paper
Aartsma-Rus, A. (2017). FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides. Nucleic Acid Therapeutics. https://doi.org/10.1089/nat.2017.0665

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.